Blog Category

Press Releases

Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel

,

/

27 October 2023

Biophytis announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap

,

/

23 October 2023

OCTOBER 13, 2023

,

/

13 October 2023

Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations

,

/

27 September 2023

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

,

/

25 September 2023

Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19

,

/

19 September 2023

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

,

/

14 September 2023

SEPTEMBER 12, 2023

,

/

12 September 2023

Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia

,

/

11 September 2023

Biophytis to Participate at the H.C. Wainwright 25 th Global Investment Conference in New York

,

/

4 September 2023

Biophytis announces next regulatory steps in Europe and the United States for its COVA project

,

/

16 August 2023

Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe

,

/

8 August 2023